Skip to main content
. 2020 Aug 15;10(22):10290–10308. doi: 10.7150/thno.46728

Figure 6.

Figure 6

ROS and Prdx2 mediate Celastrol-mediated inhibition of gastric cancer growth. (A) Measurement of tumor volumes at indicated time points following implantation of SGC-7901 cells in BALB/c mice. Mice treated with 1.5 mg/kg Celastrol, NAC with 1.5 mg/kg Celastrol, or 5 mg/kg Cisplatin. NAC was given at 1 g/L in drinking water. Celastrol and Cisplatin treatments were administered every other day. Control mice received vehicle alone. (B) Tumor weights for mice in panel A (**P<0.01, ***P<0.001). (C) Staining of tumor tissue sections harvested from mice with ROS probe DHE (red) (scale bar = 50 µm). (D) Xenograft of Prdx2 shRNA-expressing BGC-823 cells. Mice were treated with 1.5 mg/kg Celastrol every other day (Ctrl shRNA = negative control shRNA). (E) Tumor weights for mice in panel D (*P<0.05, **P<0.01, ***P<0.001). (F) Staining of tumor tissue sections harvested from mice in panel D with ROS probe DHE (red) (scale bar = 50 µm). (G) Xenograft of Prdx2 cDNA expressing (O/E) SGC-7901 cells. Mice were treated with 1.5 mg/kg Celastrol every other day (Ctrl O/E = negative vector). (H) Tumor weights for mice in panel G (*P<0.05, **P<0.01). (I) Staining of tumor tissue sections harvested from mice in panel G with ROS probe DHE (red) (scale bar = 50 µm).